Donggang Wanrui Food Co., Ltd. lacked required seafood safety plan monitoring and records for raw frozen octopus and crab.
What happened
FDA inspected the seafood processing facility on January 22, 2024 and found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation. FDA said the firm did not follow required monitoring and recordkeeping for raw octopus and crab, did not list crab and monkfish allergens in its HACCP plans, and had sanitation records fabricated after the inspection was preannounced. The firm responded February 19, 2024, but FDA said the response lacked supporting documents and a date for estimated corrective actions.
What FDA found
The firm did not follow its HACCP monitoring step requiring fishing tags and fisherman’s license for each incoming shipment of raw octopus and crab; it had no receiving records for raw materials received in 2023.
21 CFR 123.6(b)The firm did not implement its HACCP recordkeeping; production records for 2022 batches were created the week FDA preannounced the inspection.
21 CFR 123.6(b)The HACCP plans did not list allergens for crab and monkfish, both major food allergens.
21 CFR 123.6(a) and (c)(1); Food Allergen Labeling and Consumer Protection Act of 2004Sanitation monitoring records for March to November 2023 were fabricated in 2024 after FDA preannounced the inspection, not entered when observed.
21 CFR 123.11; 21 CFR 123.9(a)(4)
What FDA wants
FDA tells the firm to respond in writing within 15 working days with documentation of corrections, such as a revised HACCP plan and five consecutive days of completed monitoring records. If all corrections cannot be completed in 15 days, the firm must explain the delay and state when remaining violations will be corrected.
Who should pay attention
- US importers of frozen seafood
- brands and distributors buying from foreign seafood processors
- retailers and foodservice buyers of frozen octopus and crab
This is a summary. Read the original letter on fda.gov.